Suppl Figure from Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;−&lt;/sup&gt; Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)